Sabrina Kermiche-Rahali
Research Subjects
Research Interests
Sabrina Kermiche-Rahali has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Arnaud François
Pathology Department, Rouen University Hospital, Rouen, France
1 shared publication - Aude Di Fiore
Department of Hepatology and Gastroenterology, Rouen University Hospital, 1 Rue de Germont, 76031 Rouen, France
1 shared publication - Fanny Drieux
Department of Pathology, Rouen University Hospital, 1 Rue de Germont, 76031 Rouen, France
1 shared publication - Frédéric Di Fiore
Digestive Oncology Unit, Department of Hepato-Gastroenterology, Rouen University Hospital, Rouen, France
1 shared publication - Michel Scotté
Department of Digestive Surgery, Rouen University Hospital, Rouen Cedex, France
1 shared publication
Latest Publications
- Open Access
- 2 August 2013
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 11 (1) , 171
Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib
Sorafenib is a molecular-targeted therapy used in palliative treatment of advanced hepatocellular carcinoma (HCC) in Child-Pugh A patients. We describe the case of a patient who presented with a large HCC in the left liver associated with portal vein thrombosis (PVT). After 9 months of sorafenib treatment, reassessment showed that the tumors had decreased in size with recanalization of the portal vein. A lateral left hepatectomy was performed and pathology showed complete necrosis of the tumor. Sorafenib can downstage HCC in patients with cirrhosis allowing further surgical resection.
- 2 August 2013
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 11 (1) , 171
Open AccessComplete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib
Sorafenib is a molecular-targeted therapy used in palliative treatment of advanced hepatocellular carcinoma (HCC) in Child-Pugh A patients. We describe the case of a patient who presented with a large HCC in the left liver associated with portal vein thrombosis (PVT). After 9 months of sorafenib treatment, reassessment showed that the tumors had decreased in size with recanalization of the portal vein. A lateral left hepatectomy was performed and pathology showed complete necrosis of the tumor. Sorafenib can downstage HCC in patients with cirrhosis allowing further surgical resection.